Literature DB >> 8430068

Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene.

B Ruggeri1, M DiRado, S Y Zhang, B Bauer, T Goodrow, A J Klein-Szanto.   

Abstract

Human tobacco-related cancers exhibit a high frequency of G to T transversions in the mutation hot spot region of the p53 tumor suppressor gene, possibly the result of specific mutagens in tobacco smoke, most notably benzo[a]pyrene (B[a]P). No in vivo animal model of B[a]P-induced tumorigenesis has been used, however, to substantiate these molecular epidemiological data experimentally. Direct DNA sequence analysis of the hot spot region (exons 5-8 inclusive) of murine p53 was performed in 20 skin tumors induced by a complete carcinogenesis protocol with B[a]P. Sequence analyses revealed numerous heterozygous missense mutations in carcinomas, specifically in exons 7 and 8 of the p53 gene, and targeting exclusively guanine residues. Moreover, 70% (5/7) of the mutations characterized were G to T transversions. In contrast, direct DNA sequence analysis of 36 skin tumors induced by 7,12-dimethylbenz[a]anthracene (DMBA) in either a complete carcinogenesis protocol or in a two-stage carcinogenesis protocol revealed a 30% frequency of heterozygous p53 mutations, with the majority of mutations found in carcinomas, but only a single G to T transversion (1/8). Thus, while mutation frequencies are similar, the pattern and type of p53 mutations in B[a]P-induced skin tumors differs significantly from the mutation spectra in DMBA-induced squamous neoplasias. These in vivo findings in B[a]P-induced tumors lend support to in vitro and molecular epidemiological evidence, suggesting that the p53 tumor suppressor gene may be a selective target of metabolically activated B[a]P species etiologically associated with human tobacco-related cancers.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8430068      PMCID: PMC45801          DOI: 10.1073/pnas.90.3.1013

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Frequent mutation of the p53 gene in human esophageal cancer.

Authors:  M C Hollstein; R A Metcalf; J A Welsh; R Montesano; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

2.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

Authors:  L Raycroft; H Y Wu; G Lozano
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

3.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.

Authors:  B Bressac; M Kew; J Wands; M Ozturk
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

4.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

5.  Two oncogenes, v-fos and v-ras, cooperate to convert normal keratinocytes to squamous cell carcinoma.

Authors:  D A Greenhalgh; D J Welty; A Player; S H Yuspa
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

6.  Progressive dysplasia and aneuploidy are hallmarks of mouse skin papillomas: relevance to malignancy.

Authors:  C M Aldaz; C J Conti; A J Klein-Szanto; T J Slaga
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

7.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas.

Authors:  I C Hsu; R A Metcalf; T Sun; J A Welsh; N J Wang; C C Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

8.  Murine p53 intron sequences 5-8 and their use in polymerase chain reaction/direct sequencing analysis of p53 mutations in CD-1 mouse liver and lung tumors.

Authors:  T L Goodrow; R D Storer; K R Leander; S R Prahalada; M J van Zwieten; M O Bradley
Journal:  Mol Carcinog       Date:  1992       Impact factor: 4.784

9.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.

Authors:  I Chiba; T Takahashi; M M Nau; D D'Amico; D T Curiel; T Mitsudomi; D L Buchhagen; D Carbone; S Piantadosi; H Koga
Journal:  Oncogene       Date:  1990-10       Impact factor: 9.867

Review 10.  Chemical induction of oncogene mutations and growth factor activity in mouse skin carcinogenesis.

Authors:  B Bailleul; K Brown; M Ramsden; R J Akhurst; F Fee; A Balmain
Journal:  Environ Health Perspect       Date:  1989-05       Impact factor: 9.031

View more
  29 in total

1.  Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17.

Authors:  Juan Guinea-Viniegra; Rainer Zenz; Harald Scheuch; María Jiménez; Latifa Bakiri; Peter Petzelbauer; Erwin F Wagner
Journal:  J Clin Invest       Date:  2012-07-09       Impact factor: 14.808

2.  Enhanced aggressiveness of benzopyrene-induced squamous carcinomas in transgenic mice overexpressing the proprotein convertase PACE4 (PCSK6).

Authors:  Daniel E Bassi; Jonathan Cenna; Jirong Zhang; Edna Cukierman; Andres J Klein-Szanto
Journal:  Mol Carcinog       Date:  2014-05-21       Impact factor: 4.784

Review 3.  Dietary phytochemicals as the potential protectors against carcinogenesis and their role in cancer chemoprevention.

Authors:  Alena Liskova; Patrik Stefanicka; Marek Samec; Karel Smejkal; Pavol Zubor; Tibor Bielik; Kristina Biskupska-Bodova; Taeg Kyu Kwon; Jan Danko; Dietrich Büsselberg; Mariusz Adamek; Luis Rodrigo; Peter Kruzliak; Aleksandr Shleikin; Peter Kubatka
Journal:  Clin Exp Med       Date:  2020-02-03       Impact factor: 3.984

4.  Base pair conformation-dependent excision of benzo[a]pyrene diol epoxide-guanine adducts by human nucleotide excision repair enzymes.

Authors:  M T Hess; D Gunz; N Luneva; N E Geacintov; H Naegeli
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

5.  p53 alterations in human squamous cell carcinomas and carcinoma cell lines.

Authors:  J Caamano; S Y Zhang; E A Rosvold; B Bauer; A J Klein-Szanto
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

6.  Environmental exposure of the mouse germ line: DNA adducts in spermatozoa and formation of de novo mutations during spermatogenesis.

Authors:  Ann-Karin Olsen; Ashild Andreassen; Rajinder Singh; Richard Wiger; Nur Duale; Peter B Farmer; Gunnar Brunborg
Journal:  PLoS One       Date:  2010-06-28       Impact factor: 3.240

7.  VILIP-1 expression in vivo results in decreased mouse skin keratinocyte proliferation and tumor development.

Authors:  Jian Fu; Fang Jin; Jirong Zhang; Kathryn Fong; Daniel E Bassi; Ricardo Lopez De Cicco; Divya Ramaraju; Karl-Heinz Braunewell; Claudio Conti; Fernando Benavides; Andres J P Klein-Szanto
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

8.  Mechanisms of oral carcinogenesis induced by dibenzo[a,l]pyrene: an environmental pollutant and a tobacco smoke constituent.

Authors:  Kun-Ming Chen; Joseph B Guttenplan; Shang-Min Zhang; Cesar Aliaga; Timothy K Cooper; Yuan-Wan Sun; Joseph DelTondo; Wieslawa Kosinska; Arun K Sharma; Kun Jiang; Richard Bruggeman; Kwangmi Ahn; Shantu Amin; Karam El-Bayoumy
Journal:  Int J Cancer       Date:  2013-04-22       Impact factor: 7.396

9.  Cellular signaling crosstalk between Wnt signaling and gap junctions inbenzo[a]pyrene toxicity.

Authors:  Dong-Hoon Won; Da-Bin Hwang; Yoo-Sub Shin; Shin-Young Kim; Changuk Kim; In-Sun Hong; Byeong-Cheol Kang; Jeong-Hwan Che; Jun-Won Yun
Journal:  Cell Biol Toxicol       Date:  2021-07-20       Impact factor: 6.691

10.  Associations between polycyclic aromatic hydrocarbon-related exposures and p53 mutations in breast tumors.

Authors:  Irina Mordukhovich; Pavel Rossner; Mary Beth Terry; Regina Santella; Yu-Jing Zhang; Hanina Hibshoosh; Lorenzo Memeo; Mahesh Mansukhani; Chang-Min Long; Gail Garbowski; Meenakshi Agrawal; Mia M Gaudet; Susan E Steck; Sharon K Sagiv; Sybil M Eng; Susan L Teitelbaum; Alfred I Neugut; Kathleen Conway-Dorsey; Marilie D Gammon
Journal:  Environ Health Perspect       Date:  2009-11-18       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.